Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Tango Therapeutics, Inc.
Tango Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
Travera Inc
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Servier
Mayo Clinic
Actym Therapeutics, Inc.
Eli Lilly and Company
Jonsson Comprehensive Cancer Center
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
Eli Lilly and Company